Insulet

Insulet is a US medical-device company specialising in diabetes treatment. Its main product is Omnipod, an insulin-delivery system using small, disposable, tubeless pods designed to replace traditional insulin pumps and simplify day-to-day disease management. Its model combines system sales with a recurring component tied to ongoing pod consumption, in a market that continues to benefit from the increasing adoption of automated insulin-delivery technologies.

The shares closed on 22 September at $139.38, 2.5% below the first tradable session after the signal. The decline compressed valuation to around 20.4x forward P/E and PEG around 1.03, while TTM revenue is growing about 29% and EPS about 59%. However, the company cut its annual growth outlook due to lower Type 2 user retention, and the technical structure remains unconfirmed. The opportunity is cheaper, but operational risk has increased: 8.9.

The original assessment combines CEO Ashley McEvoy’s purchase with other insider buying.

The supplied reference price is $142.93. The 22 September close of $139.38 is around 2.5% below the first tradable session after the signal.

Q2 revenue up 23.5% and strong Omnipod expansion in the original assessment.

At the review, TTM revenue is growing around 29% and EPS around 59%, but the annual growth outlook has been reduced.

Forward P/E around 20.4x and PEG approximately 1.03 after the share-price decline.

The insider-history rating remains 9.0 in both supplied assessments.

Omnipod expansion and international growth supported the signal; revised guidance weighs on the current assessment.

Lower Type 2 user retention, reduced US guidance and operational/regulatory risks.

Technicals remain without structural confirmation; the daily rating moves from 8.0 to 6.0.

The monthly chart was already weakened by the major correction. Its rating moves from 7.0 to 6.2.

PODD · NASDAQ · USD. Ordinary share.

Update: PODD slips slightly to 8.9/10. Valuation has improved significantly and growth remains strong, but lower US guidance, reduced Type 2 retention and still-fragile technicals prevent a current 9+ confirmation.